UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Neurology, 2021-11, Vol.97 (19), p.e1870

2021

Volltextzugriff (PDF)

Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry

BMJ open, 2021-08, Vol.11 (8), p.e042480-e042480

2021

Volltextzugriff (PDF)

How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?

Journal of central nervous system disease, 2022-07, Vol.14, p.117957352211159-11795735221115912

2022

Volltextzugriff (PDF)

COVID-19 in people with multiple sclerosis: A global data sharing initiative

Multiple sclerosis, 2020-09, Vol.26 (10), p.1157-1162

2020

Volltextzugriff (PDF)

COVID-19: Status neurologischer und psychiatrischer Praxen am Beispiel des Netzwerks NeuroTransData

NeuroTransmitter, 2020-06, Vol.31 (6), p.11-14

Bergmann, Arnfin

2020

Volltextzugriff (PDF)

PHREND ® -A Real-World Data-Driven Tool Supporting Clinical Decisions to Optimize Treatment in Relapsing-Remitting Multiple Sclerosis

Frontiers in digital health, 2022-03, Vol.4, p.856829-856829

2022

Volltextzugriff (PDF)

Development of Registry Data to Create Interactive Doctor-Patient Platforms for Personalized Patient Care, Taking the Example of the DESTINY System

Frontiers in digital health, 2021-03, Vol.3, p.633427-633427

2021

Volltextzugriff (PDF)

Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry

Multiple sclerosis journal - experimental, translational and clinical, 2023-07, Vol.9 (3), p.20552173231194353-20552173231194353

2023

Volltextzugriff (PDF)

COVID-19: Status neurologischer und psychiatrischer Praxen am Beispiel des Netzwerks NeuroTransData

NeuroTransmitter, 2020-01, Vol.31 (6), p.11-14

Bergmann, Arnfin

2020

Volltextzugriff (PDF)

Erkrankte mit DiGA nicht alleine lassen

NeuroTransmitter, 2023-05, Vol.34 (5), p.16-18

2023

Volltextzugriff (PDF)

Letter to the editor on “Multiple sclerosis registries in Europe – An updated mapping survey” published in Multiple Sclerosis and Related Disorder 27 (2019) 171–178

Multiple sclerosis and related disorders, 2019-02, Vol.28, p.262-262

2019

Volltextzugriff (PDF)

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

Journal of neurology, 2018-12, Vol.265 (12), p.2980-2992

2018

Volltextzugriff (PDF)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS

Neurology, 2015-07, Vol.85 (1), p.29

2015

Volltextzugriff (PDF)

Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study

CNS drugs, 2021-09, Vol.35 (9), p.1009-1022

2021

Volltextzugriff (PDF)

Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany

Epilepsy & behavior, 2016-11, Vol.64 (Pt A), p.75-82

2016

Volltextzugriff (PDF)

Implementation of a data control framework to ensure confidentiality, integrity, and availability of high-quality real-world data registry

JAMIA open, 2022-04, Vol.5 (1)

2022

Volltextzugriff (PDF)

Implementation of a data control framework to ensure confidentiality, integrity, and availability of high-quality real-world data (RWD) in the NeuroTransData (NTD) registry

JAMIA open, 2022-04, Vol.5 (1), p.ooac017-ooac017

2022

Volltextzugriff (PDF)

1298Associations of DMT therapies with COVID-19 severity in multiple sclerosis

International journal of epidemiology, 2021-09, Vol.50 (Supplement_1)

2021

Volltextzugriff (PDF)

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis

Neurology : neuroimmunology & neuroinflammation, 2021-05, Vol.8 (3)

2021

Volltextzugriff (PDF)

Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Neurology : neuroimmunology & neuroinflammation, 2022-11, Vol.9 (6)

2022

Volltextzugriff (PDF)

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

Multiple sclerosis and related disorders, 2022-10, Vol.66, p.104072-104072, Article 104072

2022

Volltextzugriff (PDF)

The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources

International journal of MS care, 2021-11, Vol.23 (6), p.261-268

2021

Volltextzugriff (PDF)

2233 Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 DMTs deleterious for COVID-19 severity but interferons not protective among people with MS

BMJ neurology open, 2022-08, Vol.4 (Suppl 1), p.A10-A10

2022

Volltextzugriff (PDF)

The Multiple Sclerosis Data Alliance Catalogue

International journal of MS care, 2021-11, Vol.23 (6), p.261-268

2021

Volltextzugriff (PDF)

Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study

International journal of geriatric psychiatry, 2013-02, Vol.28 (2), p.164-172

2013

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(28)

Sprache

Englisch
(24)
Deutsch
(4)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis

Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry

How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?

COVID-19 in people with multiple sclerosis: A global data sharing initiative

COVID-19: Status neurologischer und psychiatrischer Praxen am Beispiel des Netzwerks NeuroTransData

PHREND ® -A Real-World Data-Driven Tool Supporting Clinical Decisions to Optimize Treatment in Relapsing-Remitting Multiple Sclerosis

Development of Registry Data to Create Interactive Doctor-Patient Platforms for Personalized Patient Care, Taking the Example of the DESTINY System

Overall and patient-specific comparative effectiveness of dimethyl fumarate versus teriflunomide: A novel approach to precision medicine applied to the German NeuroTrans Data Multiple Sclerosis Registry

COVID-19: Status neurologischer und psychiatrischer Praxen am Beispiel des Netzwerks NeuroTransData

Erkrankte mit DiGA nicht alleine lassen

Letter to the editor on “Multiple sclerosis registries in Europe – An updated mapping survey” published in Multiple Sclerosis and Related Disorder 27 (2019) 171–178

Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS

Safety, Patient-Reported Well-Being, and Physician-Reported Assessment of Walking Ability in Patients with Multiple Sclerosis for Prolonged-Release Fampridine Treatment in Routine Clinical Practice: Results of the LIBERATE Study

Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany

Implementation of a data control framework to ensure confidentiality, integrity, and availability of high-quality real-world data registry

Implementation of a data control framework to ensure confidentiality, integrity, and availability of high-quality real-world data (RWD) in the NeuroTransData (NTD) registry

1298Associations of DMT therapies with COVID-19 severity in multiple sclerosis

B-Cell Activity Predicts Response to Glatiramer Acetate and Interferon in Relapsing-Remitting Multiple Sclerosis

Updated Results of the COVID-19 in MS Global Data Sharing Initiative: Anti-CD20 and Other Risk Factors Associated With COVID-19 Severity

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

The Multiple Sclerosis Data Alliance Catalogue: Enabling Web-Based Discovery of Metadata from Real-World Multiple Sclerosis Data Sources

2233 Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 DMTs deleterious for COVID-19 severity but interferons not protective among people with MS

The Multiple Sclerosis Data Alliance Catalogue

Memantine effects measured with the Relevant Outcome Scale for Alzheimer's disease in an open-label, single-arm, multicenter clinical study

Suchergebnisse filtern